−1.84USD
−70.80 MUSD
46.02 MUSD
46.63 M
About EyePoint Pharmaceuticals, Inc.
Sector
CEO
Jay S. Duker
Headquarters
Watertown
Website
Employees (FY)
121
Founded
1987
ISIN
US30233G2093
FIGI
BBG000F90JX5
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of EYPT is 17.50 USD — it has decreased by 16.43% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange EyePoint Pharmaceuticals, Inc. stocks are traded under the ticker EYPT.
EyePoint Pharmaceuticals, Inc. is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
EYPT stock is 23.03% volatile and has beta coefficient of 2.91. Check out the list of the most volatile stocks — is EyePoint Pharmaceuticals, Inc. there?
One year price forecast for EyePoint Pharmaceuticals, Inc. has a max estimate of 68.00 USD and a min estimate of 33.00 USD.
EYPT earnings for the last quarter are −0.33 USD whereas the estimation was −0.50 USD which accounts for 33.67% surprise. Estimated earnings for the next quarter are −0.49 USD. See more details about EyePoint Pharmaceuticals, Inc. earnings.
EyePoint Pharmaceuticals, Inc. revenue for the last quarter amounts to 15.20 M USD despite the estimated figure of 7.86 M USD. In the next quarter revenue is expected to reach 8.90 M USD.
Yes, you can track EyePoint Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
EYPT stock has fallen by 20.38% compared to the previous week, the month change is a 17.30% fall, over the last year EyePoint Pharmaceuticals, Inc. has showed a 263.83% increase.
EYPT net income for the last quarter is −14.10 M USD, while the quarter before that showed −12.61 M USD of net income which accounts for −11.79% change. Track more EyePoint Pharmaceuticals, Inc. financial stats to get the full picture.
Today EyePoint Pharmaceuticals, Inc. has the market capitalization of 1.04 B, it has increased by 2.22% over the last week.
No, EYPT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, EYPT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EyePoint Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 121.00 employees. See our rating of the largest employees — is EyePoint Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EyePoint Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EyePoint Pharmaceuticals, Inc. stock shows the buy signal. See more of EyePoint Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on EyePoint Pharmaceuticals, Inc. future price: according to them, EYPT price has a max estimate of 68.00 USD and a min estimate of 33.00 USD. Read a more detailed EyePoint Pharmaceuticals, Inc. forecast: see what analysts think of EyePoint Pharmaceuticals, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EyePoint Pharmaceuticals, Inc. EBITDA is −74.60 M USD, and current EBITDA margin is −159.06%. See more stats in EyePoint Pharmaceuticals, Inc. financial statements.